JP2007522797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007522797A5 JP2007522797A5 JP2006543857A JP2006543857A JP2007522797A5 JP 2007522797 A5 JP2007522797 A5 JP 2007522797A5 JP 2006543857 A JP2006543857 A JP 2006543857A JP 2006543857 A JP2006543857 A JP 2006543857A JP 2007522797 A5 JP2007522797 A5 JP 2007522797A5
- Authority
- JP
- Japan
- Prior art keywords
- viral vector
- viral
- gene
- adenovirus
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013603 viral vector Substances 0.000 claims 37
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 239000002773 nucleotide Substances 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 230000014509 gene expression Effects 0.000 claims 12
- 239000013598 vector Substances 0.000 claims 11
- 230000001105 regulatory effect Effects 0.000 claims 10
- 241000701161 unidentified adenovirus Species 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 238000013518 transcription Methods 0.000 claims 6
- 230000035897 transcription Effects 0.000 claims 6
- 108700005077 Viral Genes Proteins 0.000 claims 5
- 210000004881 tumor cell Anatomy 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 claims 3
- 230000002103 transcriptional effect Effects 0.000 claims 3
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108010027410 Adenovirus E3 Proteins Proteins 0.000 claims 1
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 claims 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 claims 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 102000050313 human E2F1 Human genes 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/733,674 US7078030B2 (en) | 1999-11-15 | 2003-12-11 | Oncolytic adenovirus |
| US10/733,674 | 2003-12-11 | ||
| PCT/US2004/039632 WO2005060515A2 (en) | 2003-12-11 | 2004-11-23 | An oncolytic adenovirus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007522797A JP2007522797A (ja) | 2007-08-16 |
| JP2007522797A5 true JP2007522797A5 (enExample) | 2008-01-10 |
| JP4955397B2 JP4955397B2 (ja) | 2012-06-20 |
Family
ID=34710435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006543857A Expired - Fee Related JP4955397B2 (ja) | 2003-12-11 | 2004-11-23 | 腫瘍崩壊性のアデノウイルス |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7078030B2 (enExample) |
| EP (1) | EP1691765A4 (enExample) |
| JP (1) | JP4955397B2 (enExample) |
| AU (1) | AU2004304915B2 (enExample) |
| CA (1) | CA2545696A1 (enExample) |
| WO (1) | WO2005060515A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900049B2 (en) * | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US20020037274A1 (en) * | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
| US20070292396A1 (en) * | 2006-03-02 | 2007-12-20 | Juan Fueyo | Combination therapy with oncolytic adenovirus |
| CA2644743C (en) | 2006-03-08 | 2015-05-19 | Waldemar Debinski | Soluble monomeric ephrin a1 |
| US20070258952A1 (en) * | 2006-05-04 | 2007-11-08 | Baylor Research Institute | Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA |
| US20080166322A1 (en) * | 2006-12-08 | 2008-07-10 | Atkinson Richard L | Methods for producing an adenovirus type 5 gene transfer vector |
| US8309640B2 (en) | 2008-05-23 | 2012-11-13 | Sabic Innovative Plastics Ip B.V. | High dielectric constant laser direct structuring materials |
| US9296785B2 (en) | 2009-04-17 | 2016-03-29 | Wake Forest University Health Sciences | IL-13 receptor binding peptides |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| US9017672B2 (en) | 2012-05-11 | 2015-04-28 | Immunicum Aktiebolag | Hexon Tat-PTD modified adenovirus and uses thereof |
| US9868788B2 (en) | 2013-03-15 | 2018-01-16 | Wake Forest University Health Sciences | Antibodies against human and canine IL-13RA2 |
| CA2930243A1 (en) | 2013-11-11 | 2015-05-14 | Wake Forest University Health Sciences | Epha3 and multi-valent targeting of tumors |
| WO2020046130A1 (en) | 2018-08-31 | 2020-03-05 | Orca Therapeutics B.V. | Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (gsk3) and methods of killing aberrant cells |
| CN111363726A (zh) | 2018-12-26 | 2020-07-03 | 上海元宋生物技术有限公司 | 表达干扰素的溶瘤病毒及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US7001596B1 (en) * | 1999-11-15 | 2006-02-21 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
-
2003
- 2003-12-11 US US10/733,674 patent/US7078030B2/en not_active Expired - Fee Related
-
2004
- 2004-11-23 AU AU2004304915A patent/AU2004304915B2/en not_active Ceased
- 2004-11-23 EP EP04817905A patent/EP1691765A4/en not_active Withdrawn
- 2004-11-23 JP JP2006543857A patent/JP4955397B2/ja not_active Expired - Fee Related
- 2004-11-23 CA CA002545696A patent/CA2545696A1/en not_active Abandoned
- 2004-11-23 WO PCT/US2004/039632 patent/WO2005060515A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12195766B2 (en) | Tumor-selective E1a and E1b mutants | |
| US5698443A (en) | Tissue specific viral vectors | |
| JP2007522797A5 (enExample) | ||
| Sandig et al. | Optimization of the helper-dependent adenovirus system for production and potency in vivo | |
| Yamanaka et al. | Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus | |
| JP2014516536A5 (enExample) | ||
| JPH10509880A (ja) | 組織特異的複製のためのベクター | |
| JP2003528604A5 (enExample) | ||
| JP2005536231A (ja) | アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用 | |
| WO2003099859A3 (de) | Neue verwendung von adenoviren und dafür codierenden nukleinsäuren | |
| KR20010031762A (ko) | 유전자요법을 위한 과열 유도 발현 벡터 및 그의 이용 방법 | |
| CA2478616A1 (en) | Use of adenoviruses mutated in the va genes for cancer treatment | |
| WO2004005511A1 (ja) | 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス | |
| JP4361954B2 (ja) | アデノウィルス核酸を含有する医薬用組成物 | |
| ES2268695T3 (es) | Adenovirus recombinantes defectivos con una gen iva2 inactivado. | |
| Lee et al. | Oncolytic potential of E1B 55 kDa‐deleted YKL‐1 recombinant adenovirus: correlation with p53 functional status | |
| Everett et al. | Strain-specific rate of shutdown of CMV enhancer activity in murine liver confirmed by use of persistent [E1−, E2b−] adenoviral vectors | |
| CN103555765B (zh) | 一种转录调控肿瘤靶向复制溶瘤腺病毒载体、携带治疗基因腺病毒及其制备方法和应用 | |
| JP4402457B2 (ja) | アデノウイルスｅ２後期プロモーターの制御のための、インビトロにおけるｙｂ−１の使用、及び、腫瘍の治療を目的とする医薬の製造のための当該使用を活用した核酸構築物の使用 | |
| Paul et al. | Recombinant baculovirus as a highly potent vector for gene therapy of human colorectal carcinoma: molecular cloning, expression, and in vitro characterization | |
| Mei et al. | Complete replication-competent adenovirus 11p vectors with E1 or E3 insertions show improved heat stability | |
| AU2003225141A1 (en) | Alternatively spliced nucleic acid molecules | |
| WO2004106505A1 (en) | A gutless adenovirus vector and the construction method thereof | |
| Shimizu et al. | ADENOVIRUS AND OTHER DNA VIRUS VECTORS | |
| Young et al. | 480. Combined Therapies with Oncolytic Adenovirus Suppress Tumor Growth in Hamsters |